TGFB for Immuno-Oncology Drug Development Summit
Are you interested in finding the next breakthrough in immuno-oncology preclinical or clinical development?
Recent scientific, clinical breakthroughs and high-profile industry deals have reignited the race to find the next blockbuster TGF-ß inhibitor for immuno-oncology applications.
As such, the TGFß for Immuno-Oncology Drug Development Summit (January 26-28) is the ONLY industry-focused meeting dedicated to pharma, biotech, and academia who will share their latest data, best practices, and top tips to expedite TGF-beta candidates into the clinic in a safe and efficacious manner.
With over 21 expert speakers presenting across 3 days packed full of content, this is your definitive guide to tame the TGF-beta double-edged sword and navigate a narrow therapeutic window, enhance tumor suppression, and maximize therapeutic potential in immuno-oncology – you won’t want to miss it!
Here’s a sneak peek into the world-class speaker faculty:
- Shannon Turley, Senior Director, Cancer Immunology, Genentech
- Rik Derynck, Professor – Departments of Cell, Tissue Biology & Anatomy, University of California San Francisco
- Thomas Schurpf, Associate Director, Scholar Rock
- Olaf Christensen, Vice President, Head of Bintrafusp alfa, Global Development, R&D, EMD Serono
- Paul Rennert, President & Chief Scientific Officer, Aleta Biotherapeutics
- Sam Shrivastava, Chairman & Chief Executive Officer, Venn Therapeutics
- Vuong Trieu, Chairman & Chief Executive Officer, Oncotelic Inc
- Christopher Heery, Chief Medical Officer, Precision BioSciences
Download your digital event guide here to access the full speaker faculty and conference agenda.
How can this get any better I hear you ask? Well, through our specialized digital platform, you can enjoy the full conference experience all from the comfort of your own home (without the bad conference coffee and awkward encounters at the buffet table). Using our algorithm get matched with fellow attendees and speakers for meaningful networking opportunities.